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Quinidine-Induced Immune Thrombocytopenia
Mansoor N. Saleh, MD,* Nadhav Dhodaphar, MD,^ Karen Alien,* and
Albert F. LoBuglio, MD§

We have identified six cases of quinidine-induced immune thrombocytopenia based on clinical
evidence and in association with elevated amounts of platelet surface IgG. The degree of
thrombocytopenia did not correlate with severity of clinical symptoms, nor did it predict the amount of
IgG on the platelet surface. Three ofthe patients recovered promptly after drug discontinuation alone
whereas the other patients received additional corticosteroid therapy. The clinical presentation, mode
of diagnosis, arul therapeutic considerations in the treatment of drug-induced thrombocytopenia are
discussed. (Henry Ford Hosp MedJ 1989:37:28-32)

D

rugs may cause thrombocytopenia by three principal mechanisms: suppression of platelet production, direct platelet
toxicity, or antibody-mediated platelet destmction (1). With the
advent of assays specifically capable of detecting and quantifying IgG on the platelet surface (2), it has become increasingly
possible to recognize cases of drug-induced immune thrombocytopenia based on the detection of elevated levels of platelet
surface bound IgG in association with ingestion of causative
dmgs. Consequendy, dmg-induced immune thrombocytopenia
is no longer a disease diagnosed primarily by exclusion. The
occurrence of quinidine-induced thrombocytopenia, though
uncommon, was documented as early as 1965 (3) and has
been thought to be immune in origin (4,5). The platelets themselves may serve as innocent bystanders (6,7) or partial immunogens (8).
We discuss six cases of clinically documented quinidine-induced thrombocytopenia, outlining the mode of diagnosis as
well as therapeutic considerations. The '^^I-labeled monoclonal
anti-IgG assay (2) is used for the quantitation of IgG on the
platelet surface. We discuss the role of this assay in diagnosing
drug-induced immune thrombocytopenia and address its
diagnostic and prognostic value.

Materials and Methods
Patient population
Subjects were retrospectively identified from the data base of
the Immune Cytopenia Laboratory. We reviewed the charts of
all thrombocytopenic patients seen from 1983 to 1986 whose
blood samples had been sent for quantitation of antiplatelet antibodies and who at presentation were noted to be on quinidine.
Of a total of 450 samples assayed during that period, 28 index
cases were identified and further reviewed.
Selection criteria
To identify cases of quinidine-induced thrombocytopenia, patients had to have a previously known normal platelet count and

28
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a documented history of quinidine ingestion. Thrombocytopenia should have developed during quinidine therapy
and resolved after discontinuation of the dmg (with or without
additional therapy). Bone marrow evaluation was required to
document adequate marrow megakaryocytes. Patients were excluded if they had any evidence of secondary thrombocytopenia
caused by other underlying conditions. Of the 28 index cases,
six patients fulfilled the clinical criteria for quinidine-induced
thrombocytopenia. The remaining 22 patients were excluded
because of the presence of one or a combination of the following
exclusion criteria: onset of thrombocytopenia prior to starting
quinidine; thrombocytopenia secondary to hypersplenism, septicemia, or disseminated intravascular coagulation (DIC); or primary or chemotherapy-induced marrow hypoplastic state.

Determination of platelet surface bound IgG
Quantitation of IgG on the platelet surface was performed
using the radiolabeled monoclonal anti-lgG assay previously
described (9). Venous blood was collected in plastic syringes
and anticoagulated with acid citrate dextrose A. The whole
blood was centrifuged at 200 x g for 20 minutes and the
platelet-rich plasma collected. The pH was adjusted to 6.5 with
acid citrate dextrose A and then centrifuged at 1,750 X g for 20
minutes. The platelet button was thrice washed in platelet-sus-
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Table 1
Patient Characteristics
Patients
Age (years)
Sex
Race
Medical
history

Duration of
quinidine
therapy
Additional
treatment

1

2

62
M

75
F

w

3

w

Ischemic heart
disease

Diabetes mellitus.
ischemic heari
disease.
hypertension

3 months
Nitroglycerin
paste.
dipyridamole

2 years
Digoxin, insulin

4

6

5

72
M
W
Stage D prostatic
carcinoma,
hypertension.
arrhythmias

65
F
W
Ischemic heart
disease,
arrhythmias

64
.M
W
Hypertension,
ischemic heart
disease

58
M
W
Ischemic heart
disease

7 days
Isosorbide
dinitrate.
furosemide.
digoxin

3 months
Nitroglycerin
paste, almacone

5 months
Digoxin,
triamterene

3 years
Phenytoin

pension buffer (Dulbecco's phosphate buffered isotonic saline
containing 1 g/dL of bovine semm albumin and 4 mmol EDTA,
pH 6.5). Ten million washed platelets were incubated with 300
ng '^^I-labeled mouse monoclonal anti-IgG in a total volume of
300 p,L for 20 minutes at room temperature. Triplicate aliquots
of 75 |xL (2.5 X 10* platelets) were transferred to Percoll gradient tubes containing 250 p,L of isotonic 30% Percoll in saline,
centrifuged at 7,500 x g for five minutes, and the tubetipcontaining the platelet button was transected with a hemostat and
razor blade into gamma counting tubes. The number of '^'I
monoclonal antibody molecules bound per platelet was calculated based on the Avogadro number and the antibody's specific
activity and molecular weight (9).

All patients (four males and two females, ranging in age from 58
to 75 years) suffered from ischemic heart disease associated
with various arrhythmias and took quinidine in dosages ranging
from 200 mg three times daily to 648 mg every six hours (Table
1). The duration of dmg ingestion prior to presentation was
highly variable, ranging from seven days to as long as three
years. The majority of patients, however, had been on quinidine
for less than six months. In addition to quinidine, most of the
patients were on other medications (Table 1).
Clinical parameters at presentation are given in Table 2. All
but one patient were symptomatic. Symptoms consisted primarily of petechia and easy bruisibility. One patient was
asymptomatic at presentation despite a platelet count of
6,000/p.L. All six patients had a platelet count of less than
55,000/|xL, and four had a platelet count less than 10,000/p,L at
presentation. The severity of thrombocytopenia did not correlate
with symptoms at presentation, and none of the patients pre-

Results
The six patients who fulfilled the selection criteria represented clear-cut cases of quinidine-induced thrombocytopenia.

Table 2
Clinical Parameters at Presentation
Patients
I

2

5

4

3

6

Chief
complaints

Pfctechiae,
bruisibility

Asymptomatic

Bruisibility,
epistasis,
gum bleed

Petechiae,
gum bleed,
epistasis

Gum bleed

Bruisibility

Platelet nadir
(X 103/p.L)

21

6

3

1

4

4')

Antibody level*

3,561

816

1,498

7,610

1,426

1,665

Bone marrow
megakaryocytes

Increased

Increased

Increased

Increased

Increased

Increased

Coagulation
profilet

Within normal
limits

Within normal
limits

Within normal
limits

Within normal
limits

Within normal
limits

Within normal
limits

*Plitfelet surface bound IgG (moiecules IgG/plalelet).
tFVothrombin time; partial thromboplastin time.
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Table 3
Clinical Course
1

2

3

Platelet count at admission ( x IO^/IJLL)
Time point of drug discontinuation
Response to drug discontinuation alone
Additional therapy (day started)

21
DayO
Yes
None

6
DayO
Yes
None

3
DayO
Yes
None

Duration of additional therapy

—

—

Day 5
233

Time point of response
(platelet count > 100,000 JJLL)
Postrecovery platelet counts
(X 10V|xL)

6

—

4
DayO
No
Prednisone
(day 3)
7 days then
tapered
over
8 weeks

53
DayO
No
Prednisone
(day 5)
3 days

Day 11

Day 3

Day 8

Day 10

Day 8

233

286

209

206

154

Discussion
The '^'I-Iabeled monoclonal anti-IgG assay (2) was used to
quantitate levels of platelet surface bound IgG in all patients to
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5

6
DayO
No
Prednisone
(day 4)
4 days

sented witb or suffered from major bleeding such as gastrointestinal, intracranial, or pulmonary hemorrhage. Peripheral
blood smear in all patients revealed greatly decreased circulating
platelets, whereas bone marrows consistently showed increased
megakaryocytes. Complete coagulation profile was within normal limits in all patients, and no signs of bleeding diathesis were
present. Platelet surface bound IgG levels were determined in all
patients early on during their hospital course; all patients had elevated values, ranging from 816 molecules IgG/platelet in a patient with a platelet count of 6,000/p.L to 7,610 molecules IgG/
platelet in a patient with a platelet count of l,000/p,L (normal
value < 400 molecules IgG/platelet) (2,10). Platelet surface IgG
determination at recovery was performed in only one patient and
revealed a value of 400 molecules IgG/platelet.
The disease course of the six patients is summarized in Table
3. Quinidine was discontinued in all patients on the day of admission (day 0) but other medications were continued. Three patients showed a prompt increase in platelet count and complete
resolution of thrombocytopenia within three to 11 days (days 3,
5, and 11, respectively) and received no additional treatment.
The remaining three patients were started on steroid therapy between days 3 to 5 because of no apparent spontaneous improvement in platelet count up to that time. None of these patients developed bleeding symptoms beyond those noted at presentation.
Thrombocytopenia resolved in all three patients within three to
four days of steroid initiation, and steroid treatment was discontinued in two ofthese patients at that time. The remaining patient
received full dose prednisone treatment for seven days with subsequent tapering over the next eight weeks. Follow-up platelet
counts on all six patients have remained in the normal range.
The platelet profile of these patients is shown in the Figure.
The mean recovery time (platelet count > 100,000/p.L) for
the group was seven days with a range of three to 11 days. Patients who received no additional therapy showed normal
platelet counts within a mean of 6.3 days compared to 8.6 days
for patients who received steroid therapy.

30

Patients
4

document the antibody-mediated nature of this disease and to
uncover possible prognostic implications of platelet surface
bound antibody quantitation.
Differential diagnostic considerations in patients presenting
with peripheral thrombocytopenia with adequate marrow megakaryocytes include DIC, posttransfusional purpura, septicemia,
thrombotic thrombocytopenic purpura, and immune thrombocytopenic purpura (ITP), both idiopathic and dmg-induced.
Thesefivecategories can be mled out based on clinical and laboratory findings. Differentiating idiopathic immune thrombocytopenia from secondary dmg-induced thrombocytopenia
rests primarily on the prompt response and persistent remission
of the latter to dmg withdrawal with or without a short course
of corticosteroids.
Dmg-induced thrombocytopenia most commonly occurs in
the elderly (11), presumably because of their greater exposure to
such dmgs. In our patients the duration of quinidine intake was
variable, with thrombocytopenia occurring as early as seven
days to as late as three years after the start of therapy. These findings indicate that as yet undetermined host-related factors may
be responsible for the ultimate pathophysiology of the thrombocytopenic syndrome.
Despite the severity of thrombocytopenia, none of our patients experienced life-threatening bleeding. There was no correlation between symptoms at presentation and severity of
thrombocytopenia. This finding is similar to that seen in ITP
(12) and contrary to that seen in thrombocytopenia due to
myelosuppressive therapy where the incidence of life-threatening bleeding increases significantly as platelet counts fall
below 20,000/p,L (13). The increased activity of marrow
megakaryocytes and the continual production of young, hemostatically active platelets is a possible explanation for the lower
incidence of life-threatening hemorrhage in immune platelet
destruction syndromes, although the exact reason for platelet
hyperfunction in this disease is still undefined.
All patients had elevated platelet surface IgG levels, which
clearly indicates the role of antibody in this platelet destmction
process. The range of platelet surface bound IgG is similar to
that described for patients with idiopathic immune thrombocytopenia and is different (higher) than that observed in non-
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immune thrombocytopenia (10). The monoclonal anti-IgG assay used in this study differs from assays previously used to
quantitate platelet IgG levels in that it measures surface bound
IgG rather than total cellular IgG and utilizes a high affinity
monoclonal antibody in a direct binding method (2,9,10,14). We
found no relationship between the severity of thrombocytopenia
and the level of platelet bound IgG in our six patients, which is
consistent with findings in ITP and divergent from previously
published reports using different assay techniques (10,15). Our
finding is not unexpected since a multitude of host-related
factors as well as factors related to heterogeneity in terms of
subclass content and surface distribution of antibody on the cell
surface may determine the ultimate destruction rate of the
opsonized target (16,17).
Three of the six patients responded promptly to discontinuation of quinidine with full platelet count recovery within one,
three, and five days, respectively. The remaining three patients
were started on prednisone therapy, although there was no
clinical indication of worsening of any of the symptoms noted at
presentation. These patients did not show any spontaneous increment in platelet count three to five days after discontinuing
quinidine. Whether the lack of prompt response to dmg discontinuation was related to the persistence of circulating dmg levels
due to delayed clearance/degradation in these patients is unclear.
The presence of the offending agent appears to be a prerequisite
for the pathogenesis of thrombocytopenia (18). All three patients
started on prednisone therapy (1 mg/kg/day) achieved platelet
counts of > 100,000/p,L within three to four days. Whether this
prompt effect could have been achieved without prednisone
therapy is speculative. Prednisone was immediately discontinued in two patients and subsequently tapered over the ensuing
eight weeks in the third patient. All three patients maintained
normal platelet counts when off steroid therapy. In evaluating
the overall clinical course of the patients who received prednisone and those who did not, no difference existed in duration
of thrombocytopenia, platelet count at recovery, or symptoms
during the hospital course. Initial platelet counts as well as
platelet surface bound IgG levels were not significantiy different
in the two groups.
Use of corticosteroids in the treatment of drug-induced
thrombocytopenia remains a clinical judgment call. In the absence of readily available in vitro assays to detect quinidine-dependent antibodies, the following three therapeutic altematives
appear equally acceptable: drug withdrawal accompanied by
corticosteroid treatment, drug withdrawal followed by corticosteroid therapy three days later if no reversal of thrombocytopenia is evident, and dmg withdrawal with careful observation of platelet count. Patients with dmg-induced thrombocytopenia respond promptly to platelet transfusion with
adequate hemostasis (19). Thus, patients under observation can
be readily managed with platelet support in the event of a potentially life-threatening hemorrhage. In our opinion, most patients
can be adequately managed with dmg discontinuation and close
follow-up without institution of additional therapy.
These six cases of quinidine-induced immune thrombocytopenia were identified based on clinical evidence (quinidine
therapy, prompt response to dmg cessation with or without corticosteroids, and lack of dependence on corticosteroids for con-
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Figure—Platelet count profile of study patients.

tinual remission) in association with elevated platelet surface
IgG. Kelton et al (15) have documented the presence of antibody
in the serum of such patients which reacts with platelets in a
dmg-dependent fashion. Obviously, such an assay, if available,
is useful for confirming the dmg-dependent mechanism. However, such assays are commonly not available or not available in
fime to be helpful in individual patient care decisions.
We feel that new onset of thrombocytopenia in the setting of
quinidine administration (particularly if antibody is present on
platelet surface) should allow a working diagnosis of drug-induced thrombocytopenia. Treatment should be prompt dmg cessation. Depending on clinical evidence, corticosteroids may be
added but should be stopped, with subsequent monitoring of
platelet count, once the platelet count increases. Persistent normal counts confirm the diagnosis of a dmg-dependent syndrome
since virtually all patients with idiopathic or secondary immune
thrombocytopenia will relapse after seven to ten days of corticosteroid treatment. This approach also limits patient exposure
to the serious side effects of corticosteroid therapy.
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